Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease

Behav Brain Res. 2016 Dec 15:315:1-9. doi: 10.1016/j.bbr.2016.08.018. Epub 2016 Aug 8.

Abstract

Levodopa (l-DOPA) has been proved to reverse the pathologic neuron activities in many brain regions related to Parkinson's disease (PD). But little is known about the effect of l-DOPA on the altered electrophysiological coherent activities between pedunculopontine nucleus (PPN) and motor cortex. To investigate this, local field potentials (LFPs) of PPN and primary motor cortex (M1) were recorded simultaneously in control, 6-hydroxydopamine lesioned and lesioned rats with l-DOPA chronic treatment. The results revealed that in resting state, chronic l-DOPA treatment could correct the suppressed power of LFPs in PPN and M1 in low-frequency band (1-7Hz) and the enhanced power in high-frequency band (7-70Hz in PPN and 12-70Hz in M1) of lesioned rats. In locomotor state, l-DOPA treatment could correct the alterations in most of frequency bands except the δ band in PPN and α band in M1. Moreover, l-DOPA could also reverse the altered coherent relationships caused by dopamine depletion in resting state between PPN and M1 in β band. And in locomotor state, l-DOPA had therapeutic effect on the alterations in δ and β bands but not in the α band. These findings provide evidence that l-DOPA can reverse the altered LFP activities in PPN and M1 and their relationships in a rat model of PD, which contributes to better understanding the electrophysiological mechanisms of the pathophysiology and therapy of PD.

Keywords: Coherence; Levodopa; Local field potential; Parkinson’s disease; Primary motor cortex; The pedunculopontine nucleus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Benserazide / pharmacology
  • Benserazide / therapeutic use
  • Conditioning, Operant / drug effects
  • Disease Models, Animal
  • Evoked Potentials / drug effects*
  • Fourier Analysis
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Locomotion / drug effects
  • Male
  • Motor Cortex / drug effects*
  • Oxidopamine / toxicity
  • Parkinson Disease / drug therapy
  • Parkinson Disease / etiology
  • Parkinson Disease / pathology*
  • Pedunculopontine Tegmental Nucleus / drug effects*
  • Rats
  • Rats, Wistar
  • Time Factors

Substances

  • Antiparkinson Agents
  • Levodopa
  • Benserazide
  • Oxidopamine